#immunogenicity — Thursday, September 10, 2026 (1 items)
| 0 | ℹ |
Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial.
(linkinghub.elsevier.com)
|
Lancet Infectious Diseases 2026-09-10 | #vaccination #influenza #immunogenicity #adjuvant #immunity |